Dr. Mark Andrew Hallman, MD, PhD

Dr. Hallman practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Hallman's NPI, 1124256557, was assigned on June 24, 2009. Dr. Hallman graduated from Medical University of South Carolina (MUSC) in 2009. Dr. Hallman holds Pennsylvania license MT197482.

Dr. Hallman's primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Hallman's primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Hallman is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Hallman to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hallman practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hallman's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hallman is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Hallman's licenses on file in 2 states: Pennsylvania and South Carolina.

Dmand AI lists bladder cancer radiation, bone cancer radiation, cancer radiation-upper GI, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Hallman treats.

CMS data shows 1,690 Medicare services from Dr. Hallman across 12 procedure codes in 2024, for 284 Medicare patients. Medicare paid $126,790 for them.

CMS counts 284 Medicare patients who saw Dr. Hallman in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have cancer, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hallman's median patient age at 73, with 12% women.

In 2024, Dr. Hallman wrote 395 Medicare Part D claims for 118 patients. 91% of them were for generic drugs. CMS names the drug for 306 of them, across 2 drugs with 11 or more claims each, at $38,998 in total drug cost. In 2023, CMS named 294 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Hallman for performance year 2024, reported as part of a group. Dr. Hallman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hallman as offering telehealth.

Dmand AI links 29 papers to Dr. Hallman, published from 2008 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Radiotherapy Dosage and Brachytherapy. Dr. Hallman has published most often in Brachytherapy. Dr. Hallman's most frequent co-authors are Eric Mark Horwitz, MD, David Yen Tang Chen, MD and Mark L. Sobczak, MD.

CMS Open Payments shows 6 general payments to Dr. Hallman from 4 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $82.

Dmand AI lists 1 award for Dr. Hallman, most recently Alpha Omega Alpha Medical Honor Society in 2009.

Dr. Hallman graduated from Medical University of South Carolina (MUSC) in 2009.

Dr. Hallman is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.